Empagliflozin; Linagliptin Patent Expiration
Empagliflozin; Linagliptin is Used for managing type 2 diabetes mellitus, including in patients with renal impairment, through the administration of drugs such as linagliptin and empagliflozin. It was first introduced by Boehringer Ingelheim
Empagliflozin; Linagliptin Patents
Given below is the list of patents protecting Empagliflozin; Linagliptin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Glyxambi |
US10258637 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Glyxambi |
US11090323 (Pediatric) | Pharmaceutical composition, methods for treating and uses thereof | Oct 03, 2034 | Boehringer Ingelheim |
| Glyxambi | US9949998 | Pharmaceutical composition, methods for treating and uses thereof | Jun 11, 2034 | Boehringer Ingelheim |
| Glyxambi | US10258637 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Glyxambi | US11090323 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Glyxambi | US11833166 | Pharmaceutical composition, methods for treating and uses thereof | Apr 03, 2034 | Boehringer Ingelheim |
| Glyxambi | US10406172 | Pharmaceutical composition, methods for treating and uses thereof | Jun 15, 2030 | Boehringer Ingelheim |
| Glyxambi | US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor | Jun 04, 2030 | Boehringer Ingelheim |
| Glyxambi |
US8551957 (Pediatric) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate | Apr 14, 2030 | Boehringer Ingelheim |
| Glyxambi | US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate | Oct 14, 2029 | Boehringer Ingelheim |
| Glyxambi |
US7579449 (Pediatric) | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Feb 01, 2029 | Boehringer Ingelheim |
| Glyxambi | US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | Aug 01, 2028 | Boehringer Ingelheim |
| Glyxambi |
US11033552 (Pediatric) | DPP IV inhibitor formulations | Nov 04, 2027 | Boehringer Ingelheim |
| Glyxambi |
US8673927 (Pediatric) | Uses of DPP-IV inhibitors | Nov 04, 2027 | Boehringer Ingelheim |
| Glyxambi |
US7713938 (Pediatric) | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Oct 15, 2027 | Boehringer Ingelheim |
| Glyxambi | US11033552 | DPP IV inhibitor formulations | May 04, 2027 | Boehringer Ingelheim |
| Glyxambi | US8673927 | Uses of DPP-IV inhibitors | May 04, 2027 | Boehringer Ingelheim |
| Glyxambi | US9173859 | Uses of DPP IV inhibitors | May 04, 2027 | Boehringer Ingelheim |
| Glyxambi | US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments | Apr 15, 2027 | Boehringer Ingelheim |
| Glyxambi |
US8883805 (Pediatric) | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines | May 26, 2026 | Boehringer Ingelheim |
| Glyxambi | US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines | Nov 26, 2025 | Boehringer Ingelheim |
| Glyxambi |
US7407955 (Pediatric) | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | Nov 02, 2025 | Boehringer Ingelheim |
| Glyxambi | US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions | May 02, 2025 | Boehringer Ingelheim |
| Glyxambi | US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug 12, 2023
(Expired) | Boehringer Ingelheim |
| Glyxambi | US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug 12, 2023
(Expired) | Boehringer Ingelheim |
| Glyxambi | US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Boehringer Ingelheim |
| Glyxambi | US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Boehringer Ingelheim |
| Glyxambi | US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
Feb 02, 2019
(Expired) | Boehringer Ingelheim |
| Glyxambi | US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr 24, 2017
(Expired) | Boehringer Ingelheim |
Empagliflozin; Linagliptin's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List